158 related articles for article (PubMed ID: 34279176)
1. Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
Dunn KA; Forbrigger Z; Connors J; Rahman M; Cohen A; Van Limbergen J; Langille MGI; Stadnyk AW; Bielawski JP; Penny SL; MacDonald T; Kulkarni K
Leuk Lymphoma; 2021 Dec; 62(13):3244-3255. PubMed ID: 34279176
[TBL] [Abstract][Full Text] [Related]
2. Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
Dunn KA; Connors J; Bielawski JP; Nearing JT; Langille MGI; Van Limbergen J; Fernandez CV; MacDonald T; Kulkarni K
Leuk Lymphoma; 2021 Apr; 62(4):927-936. PubMed ID: 33258724
[TBL] [Abstract][Full Text] [Related]
3. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
[TBL] [Abstract][Full Text] [Related]
5. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
[TBL] [Abstract][Full Text] [Related]
6. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
7. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
8. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
9. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
10. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia.
Kaminski KS; Beach CL; Peden DB; Le U; Roehrs PA
J Oncol Pharm Pract; 2016 Apr; 22(2):354-6. PubMed ID: 25567519
[TBL] [Abstract][Full Text] [Related]
11. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia.
Nookala Krishnamurthy M; Narula G; Gandhi K; Awase A; Pandit R; Raut S; Singh R; Gota V; Banavali SD
JCO Glob Oncol; 2020 Jul; 6():1009-1016. PubMed ID: 32628582
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
Douer D; Yampolsky H; Cohen LJ; Watkins K; Levine AM; Periclou AP; Avramis VI
Blood; 2007 Apr; 109(7):2744-50. PubMed ID: 17132721
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
16. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of asparaginase activity levels following treatment with pegaspargase.
Bleyer A; Asselin BL; Koontz SE; Hunger SP
Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
[TBL] [Abstract][Full Text] [Related]
18. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Geyer MB; Ritchie EK; Rao AV; Vemuri S; Flynn J; Hsu M; Devlin SM; Roshal M; Gao Q; Shukla M; Salcedo JM; Maslak P; Tallman MS; Douer D; Park JH
Haematologica; 2021 Aug; 106(8):2086-2094. PubMed ID: 33054114
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
